Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance

By Mark Prvulovic - Feb 14, 2020 at 7:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the pharmaceutical giant are down 4.3% in light of the news.

AstraZeneca (AZN 3.80%) announced its fourth-quarter and 2019 full-year financial results on Friday morning. While the company reported impressive sales growth in a number of its top-selling drugs, investors are worried that the novel coronavirus outbreak could significantly eat away at the company's 2020 sales.

Revenue came in at $6.7 billion, a 3.8% increase from last year. Product sales accounted for the majority of this figure, around $6.25 billion, which is up a healthy 8.4% from Q4 2018. The remaining $414 million came from collaboration revenue, which has shrunk by 36.2%. In terms of specific products, AstraZeneca's non-small cell lung cancer drug Tagrisso brought in $884 million in revenue, a 49% increase from last year. Another top performer for the company, a cancer drug called Imfinzi, is up 62% from Q4 2018 and brought in $424 million.

A person standing on a stock arrow that's going down.

Image source: Getty Images.

Despite strong growth in a number of the company's drugs, the bottom line remains less than impressive. Profit after tax came in at only $277 million for the quarter, which is a 72% decline from last year.

What's in store for the future?

The pharmaceutical giant also warned that 2020 revenues could be significantly impacted due to the coronavirus epidemic. Chinese sales have been a major revenue driver for AstraZeneca, which grew 35% in 2019 alone. Considering China is the AstraZeneca's fastest-growing market, the company's growth prospects for 2020 could be significantly hampered by further outbreaks of the coronavirus.

The company's 2020 guidance expects high-single-digit to low-double-digit percentage increases in revenue assuming that the coronavirus doesn't last more than a few months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.90 (3.80%) $2.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.